2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1565

Depression and Fatigue in Patients with Ankylosing Spondylitis
Abstract Number: 121

Depression As a Risk Factor for the Development of Rheumatoid Arthritis: A Population-Based Cohort Study
Abstract Number: 162

Depression Versus Frustration
Abstract Number: 2159

Dermatomyositis Acute Onset/Flares Following Ingestion of Isalean® Herbal Supplement: Clinical and Immunostimulatory Findings
Abstract Number: 2477

Descriptive Patterns of Switches and Swaps in Patients with Rheumatoid Arthritis Initially Treated with Anti-TNF Agents in First Intention between 2000 and 2006, and 2007 and 2015 – Experience from a Real-World Database RHUMADATA®
Abstract Number: 2973

Detection of Clinical Signs of Arthritis and Subclinical Evidence of Inflammation in Psoriasis Patients with Risk for Arthritis: Value of Clinical Examination, Ultrasound and Fluorescence-Optical Imaging – Results from the Prospective Multicentre Xciting Study
Abstract Number: 704

Detection of dsDNA Antibodies By New Fluoroimmunoassay with Comparable Diagnostic Sensitivity and Specificity to Farr-Ria
Abstract Number: 1802

Detection of Flare over the Past 3 Months in Rheumatoid Arthritis: Cross-Cultural Equivalence of the Self-Report Flare-RA Questionnaire
Abstract Number: 870

Detection of Left Ventricular Regional Function in Rheumatoid Arthritis Patients without Cardiac Symptons, As Assessed By Feature Tracking Cardiac Magnetic Resonance Imaging
Abstract Number: 1997

Detection of Progression of Radiographic Damage Despite Early and Targeted Therapy in Inflammatory Arthritis Using High-Resolution Peripheral Quantitative Computed Tomography
Abstract Number: 587

Detection of Structural Lesions on T1 Weighted MRI Versus Radiography of the Sacroiliac Joints in Early Axial Spa: 2-Year Data
Abstract Number: 2286

Determinants of Anti-Tumor Necrosis Factor Drug Use in Juvenile Spondyloarthropathy and Impact on Clinical Disease Outcomes
Abstract Number: 357

Determinants of Patient and Physician Disagreement on Presence of a Gout Flare
Abstract Number: 1537

Determinants of Patient-Reported Improvement after Administration of Biological Treatment in Axial Spondyloarthritis: A Cross-Sectional Study
Abstract Number: 1031

Developing a Multi-Phase Claims-Based Algorithm to Facilitate the Study of Drug Exposure during Pregnancy

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].